April D Kimmel1,2, Daniel W Fitzgerald3, Jean W Pape3,4, Bruce R Schackman2. 1. Virginia Commonwealth University School of Medicine, Richmond, VA, USA (ADK) 2. Department of Public Health, Weill Cornell Medical College, New York, NY, USA(ADK, BRS), 3. Department of Medicine, Weill Cornell Medical College, New York, NY, USA(DWF, JWP) 4. Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO), Port-au-Prince, Haiti (JWP)
Abstract
BACKGROUND: International guidelines recommend HIV treatment expansion in resource-limited settings, but funding availability is uncertain. We evaluated the performance of a model that forecasts lives saved through continued HIV treatment expansion in Haiti. METHODS: We developed a computer-based, mathematical model of HIV disease and used incidence density analysis of patient-level Haitian data to derive model parameters for HIV disease progression. We assessed the internal validity of model predictions and internally calibrated model inputs when model predictions did not fit the patient-level data. We then derived uncertain model inputs related to diagnosis and linkage to care, pretreatment retention, and enrollment on HIV treatment through an external calibration process that selected input values by comparing model predictions to Haitian population-level data. Model performance was measured by fit to event-free survival (patient level) and number receiving HIV treatment over time (population level). RESULTS: For a cohort of newly HIV-infected individuals with no access to HIV treatment, the model predicts median AIDS-free survival of 9.0 years precalibration and 6.6 years postcalibration v. 5.8 years (95% confidence interval, 5.1-7.0) from the patient-level data. After internal validation and calibration, 16 of 17 event-free survival measures (94%) had a mean percentage deviation between model predictions and the empiric data of <6%. After external calibration, the percentage deviation between model predictions and population-level data on the number on HIV treatment was <1% over time. CONCLUSIONS: Validation and calibration resulted in a good-fitting model appropriate for health policy decision making. Using local data in a policy model-building process is feasible in resource-limited settings.
BACKGROUND: International guidelines recommend HIV treatment expansion in resource-limited settings, but funding availability is uncertain. We evaluated the performance of a model that forecasts lives saved through continued HIV treatment expansion in Haiti. METHODS: We developed a computer-based, mathematical model of HIV disease and used incidence density analysis of patient-level Haitian data to derive model parameters for HIV disease progression. We assessed the internal validity of model predictions and internally calibrated model inputs when model predictions did not fit the patient-level data. We then derived uncertain model inputs related to diagnosis and linkage to care, pretreatment retention, and enrollment on HIV treatment through an external calibration process that selected input values by comparing model predictions to Haitian population-level data. Model performance was measured by fit to event-free survival (patient level) and number receiving HIV treatment over time (population level). RESULTS: For a cohort of newly HIV-infected individuals with no access to HIV treatment, the model predicts median AIDS-free survival of 9.0 years precalibration and 6.6 years postcalibration v. 5.8 years (95% confidence interval, 5.1-7.0) from the patient-level data. After internal validation and calibration, 16 of 17 event-free survival measures (94%) had a mean percentage deviation between model predictions and the empiric data of <6%. After external calibration, the percentage deviation between model predictions and population-level data on the number on HIV treatment was <1% over time. CONCLUSIONS: Validation and calibration resulted in a good-fitting model appropriate for health policy decision making. Using local data in a policy model-building process is feasible in resource-limited settings.
Authors: D W Fitzgerald; P Severe; P Joseph; L R Mellon; E Noel; W D Johnson; J W Pape Journal: J Acquir Immune Defic Syndr Date: 2001-11-01 Impact factor: 3.731
Authors: Paul E Sax; Runa Islam; Rochelle P Walensky; Elena Losina; Milton C Weinstein; Sue J Goldie; Sara N Sadownik; Kenneth A Freedberg Journal: Clin Infect Dis Date: 2005-09-23 Impact factor: 9.079
Authors: X Anglaret; G Chêne; A Attia; S Toure; S Lafont; P Combe; K Manlan; T N'Dri-Yoman; R Salamon Journal: Lancet Date: 1999-05-01 Impact factor: 79.321